GlassScriptPhysician profile
Allison R White
NPI 1760559751
$4,345.63
in general payments reported to CMS, 2019-2025
13 companies · $3,604 in 2025
The $3,604 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.38 · 2020: $230 · 2021: $136 · 2022: $155 · 2023: $16.58 · 2024: $167 · 2025: $3,604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $3,328 · Food and Beverage: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $3,328.00 |
| Food and Beverage | $458.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $3,328.00 | 2025 | Rs-4i Plus With Intersperse |
| Fresenius USA Marketing, INC. | $412.43 | 2020-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $151.99 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.38 | 2020-2021 | |
| Akebia Therapeutics INC | $72.11 | 2019-2020 | |
| Baxter Healthcare | $61.27 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $34.54 | 2020 | |
| Amgen INC. | $34.28 | 2020-2022 | |
| Travere Therapeutics, INC. | $31.83 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.78 | 2020 | |
| Glaxosmithkline, LLC. | $22.92 | 2022 | |
| Stemline Therapeutics INC. | $16.58 | 2023 | Orserdu |
| Ardelyx, INC. | $15.52 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.